BIO-Europe 2025: Topas Therapeutics is delivering nanoparticles to the liver to establish tolerance in T-cells for autoimmune and immune-mediated disease - it recently had intriguing data in celiac
CEO Hugo Fry describes the scientific idea behind antigenic tolerization, and discusses Topas' recent PoC data that was presented at Digestive Disease Week.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.